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ABSTRACT
Background: The mortality rate from pneumonia remains very high, reaching 15% in the United States while in 
Indonesia pneumonia is the second leading cause of death. Antibiotics improve outcomes in those with bacterial 
pneumonia. Irrational antibiotic therapy impacts to bacteria resistance, potentially increasing side effects of drugs, 
prolonged patient’s length of stay and higher total hospital costs. 
Aim: This study aimed to improve the service quality by calculating the percentage of irrational antibiotic therapy 
based on Gyssens workfl ow and the additional total of consumables antibiotics costs.
Methods: The study design was retrospective, including 57 pneumonia inpatients in internal medicine department 
wards in Dr. Sardjito Hospital, from November 2011 to January 2012. Statistical analyses were conducted by 
using Mann-Whitney U test.
Results: From 57 pneumonia inpatients, irrational antibiotic therapy reached 68,4% (39 of 57 patients). 
Azithromycin was misused and overused antibiotic.  Total excess cost of daily antibiotic were Rp 294,000.00 
and consumables antibiotics were Rp 215,000.00
Conclusion: Irrational antibiotic therapy in pneumonia is associated with and an overall impacts on healthcare 
costs.
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INTRODUCTION 
The pneumonia mortality rate remains is very high, 
reaching 15% in the United States while in Indonesia 
as the second leading cause of death. An empirical 
antibiotic therapy is the primary treatment to decrease 
the mortality rate of pneumonia, as defi nitive therapy 
requires bacterial culture. Irrational empirical antibiotic 
therapy impacts to the bacterial resistance, potentially 
increasing side effects of drugs, prolonged patient’s 
length of stay and higher total hospital cost. This study 
aims to improve the service quality by calculating the 
percentage of irrational empirical antibiotic therapy 
based on Gyssens groove in Dr. Sardjito hospital and 
excess of antibiotic costs and the associated additional 
costs.
METHOD
This study used secondary data of pneumonia 
patients admitted to Internal Medicine Ward Dr. Sardjito 
hospital from November 2011 to January 2012. Subjects 
were all patients with a diagnosis of pneumonia and 
admitted to Internal Medicine Ward Sardjito Hospital 
from November 2011 to January 2012. Patients 
hospitalized or died ≤48 hours, had incomplete medical 
records, and refer to intensive care unit were excluded. 
Demographic data, height and weight, vital signs, types 
of fi nancing, type of antibiotic, duration, dose, route of 
antibiotics administration, co-morbid, laboratory data, 
bacterial culture, x-rays, patient fi nancing and real data 
is per item, length of stay, and reason for discharge from 
the hospital. Qualitative assessment of the rationality of 
antibiotic is using Gyssens groove. Guidelines empirical 
antibiotic therapy on pneumonia is using ATS (American 
Thoracic Socciety) guidelines. Statistical analyses were 
conducted by using Mann-Whitney U test.
RESULTS
Baseline characteristics of fi fty-seven patients 
with a diagnosis of pneumonia were summarized in 
Table 1.
The subjects predominantly male gender with 
61.4% with 59, 6% were less than 60 years old. Length 
of stay more than 7 days was 73.7% and 43.9%. 
The type of insurance was Jamkesmas. Diagnosis of 
community acquired pneumonia were 82.5% (47 of 57 
patients), and 61, 4% patient had > 4 co-morbidities.
Cephalosporin were used more than 50%, and 
were given intravenously, the irrational use of antibiotics 
is dominated by the use of azytromisin G2C (Gyssens 
2c) or wrong route of administration (orally) (Table 
2). Overall irrational use of antibiotics in Dr. Sardjito 
hospitals reached 68.4% (Table 3).
Table 4 show antibiotic costs per day have a 
minimum value of IDR 5025.00 while the maximum 
value reached IDR 1,847,870.86. Magnitude of 
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Table 1. Baseline characteristic
Characteristics of Subjects Count  (N = 57) Percentage (%)
Sex
Malea. 
Femaleb. 
35
22
61,4%
38,6%
Age (Years)
< 60a. 
≥ 60b. 
34
23
59,6%
40,4%
Method of payment
Generala. 
Jamkesmasb. 
Jamkesdac. 
Mandatory health insuranced. 
7
25
6
19
12,1%
43,9%
10,5%
33,3%
Length of stay (days)
< 7a. 
≥ 7b. 
15
42
26,3%
73,7%
Reason for leaving hospital
Permitteda. 
At  his own requestb. 
Diedc. 
31
13
13
54,4%
22,8%
22,8%
Count of co-morbidities
0a. 
1-3b. 
4-5c. 
3
19
35
5,3%
33,3%
61,4%
Co-morbidities
Malignancya. 
Chronic kidney diseases b. 
(CKD)
Congestive Heart Failure c. 
(CHF)
Sepsisd. 
Diabetus mellituse. 
Othersf. 
30
24
20
22
15
59
17,6%
14,1%
11,8%
12,9%
8,8%
34,7%
Diagnosis
Pneumonia communitya. 
Pneumonia nosocomialb. 
47
10
82,5%
17,5%
Table 2. Types of Antibiotics and Rationality Use by Gyssens
Antibiotics Count Percentage (%)
Ceftriaxone G1,G1,G1,G1,G1,G1,G1,G1,G1
G1,G1,G1,G1,G1,G1,G1,G1,G1
G1,G1,G1,G1,G2b,G2b,G2b,G3a
G3b,G4a,G4a,G4a,G4a,G5,-
33,3%
Azytromisine G1,G2a,G2a,G2c,G2c,G2c,G2c,G2c
G2c,G2c,G2c,G2c,G2c,G2c,G2c,G2c
G2c,G2c,G2c,G2c,G2c,G3a,G3a,G3a
G3a,G3a,G3a,G3b,G3b,G5,-
31,3%
Ceftazidime G1,G1,G1,G1,G1,G1,G1,G1,G1,G1,
G1,G1,G1,G2b,G3a,G3b,G3b,G3b,
G4a,G4a,-
20,8%
Metronidazole G1,G1,G1,G1,G1,- 5,2%
Ciprofl oxascin G1,G1,G1,G2b,- 4,2%
Cefotaxime G1,G1,G3b,G4c,- 4,2%
Gentamisine G1,G1,G1,- 3,1%
Imipenem G1,G2b,G2b,- 3,1%
Information: G1: Gyssen 1; G2a : Gyssen 2a; G2b: Gyssen 2b; G2c: Gyssen 2c; 
; G3a : Gyssen 3a; G3b: Gyssen 3b; G3c: Gyssen 3c; ; G4a : Gyssen 4a; G4c: 
Gyssen 4c; G5: Gyssen 5; 
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daily consumables cost has a minimum value and a 
maximum value of IDR 35095.00-IDR. 943,638.25. 
Mann-Whitney test p = 0.328 obtained fi gures on 
the cost of antibiotics per day the amount of IDR 
294,000.00. Therefore, the value of p > 0.05 then 
there is no signifi cant difference between the cost of 
antibiotics every day rational and the irrational. With 
the same test p = 0.020 obtained fi gures on the cost of 
consumables per day amounting to IDR 215,000.00. 
Where the value of p < 0.05 then there is a signifi cant 
difference between the cost of consumables every 
day that rational and irrational.
DISCUSSION
Characteristics of the sample are dominated by 
male gender (61.4%), this corresponds to literature 
that smoking in men is a risk factor for pneumonia.1,28 
Most patients were <60 years (59.6%), contrast to 
the literature where older age were more at risk. This 
difference is caused by the first study conducted 
in a hospital, so the less reflect actual conditions, 
both community and hospital acquired pneumonia. 
Community acquired pneumonia is dominated by 
immune compromise patients so young age are 
particularly vulnerable to pneumonia.
Patients with co-morbid > 4 reached 61.4%, 
where count of co-morbidities is not directly proportional 
to the magnitude of mortality but rather is determined by 
its degree of severity of co-morbidity. Most co-morbid 
were malignancies (17.6%), followed by 14.1% CKD, 
11.8% CHF and 8.8% DM in accordance with a PORT 
score system.
These results (68,4%) are not much different 
from the research conducted by Amrin at Dr. Soetomo 
hospital Surabaya in 2002 Surabaya in 2002 where 
the irrational use of antibiotics reached 55-80%.15 
Route of administration of drugs without azithromicin 
more appropriate than when given azithromicin.11 
According to the ATS 2001 azytromisin that should be 
given intravenously. Different dosing greatly affect the 
pharmacodynamics and pharmacokinetics of the drug, 
so the drug target and effectiveness is diminished or 
not functioning.10,17
From an economic standpoint, the question is 
whether the cost or expense of profi ts. The meaning 
of the advantages of this study is to heal in a short 
time with an optimal tool. When the objective 
component, the time and the tools are not achieved 
regarded as waste. From the description above, the 
waste of irrational antibiotic for pneumonia who was 
admitted to the Internal Medicine ward DR Sardjito 
Rp 294,000.00 while the consumable waste reached 
Rp 215,000.00.
CONCLUSION
Irrational antibiotic therapy in pneumonia patients 
in Dr. Sardjito reached 68.4% with the excess cost of 
daily antibiotic expenditure were Rp. 294,000.00 while 
the consumables cost Rp. 215,000.00.
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